Vimarsana
Biggest News Aggregation in the World

Page 4 - Gary Glick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gary Glick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gary Glick Today - Breaking & Trending Today

Financing roundup: Neumora refuels, Ascidian ascends, Mablink's moves & more - Vimarsana News

Financing roundup: Neumora refuels, Ascidian ascends, Mablink's moves & more

Odyssey Therapeutics raised $168 million in Series B financing, the largest round of funding for a biotech startup this week. Companies developing new technologies in genetic diseases, cancer, and drug research are represented also represented in this week’s recap of life science financings.

Odyssey recruits news investors to fund precision drug research - Vimarsana News

Odyssey recruits news investors to fund precision drug research

BioPharma

Post-Dobbs, States Seek to Define Laws Around Abortion Access | Morgan Lewis - Vimarsana News

Post-Dobbs, States Seek to Define Laws Around Abortion Access | Morgan Lewis

The US Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization put the onus on states to define laws around access to abortion-related services. As expected, the two...

Coastal News Today | TX - Diving Deep for Vital Marine Carbon Sequestration Research - Vimarsana News

Coastal News Today | TX - Diving Deep for Vital Marine Carbon Sequestration Research

Enbridge-funded study will examine artificial reef off Texas coast, explore possibility of reducing society’s carbon footprint

Charm Therapeutics: CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology - Vimarsana News

Charm Therapeutics: CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

PRESS RELEASE CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug